Lieff Cabraser Civil Justice Blog
Elizabeth Cabraser to Serve as Featured Faculty in Class Action Symposium at Lewis and Clark Law School

Elizabeth Cabraser to Serve as Featured Faculty in Class Action Symposium at Lewis and Clark Law School

Lieff Cabraser founding partner Elizabeth Cabraser will serve as Featured Faculty at an academic symposium for attorneys, law professors and students, judges, law clerks, and public officials, entitled “Class Actions, Mass Torts, and MDLs: The Next 50 Years” taking place Nov. 1-2, 2019 at Lewis & Clark Law School in Portland Oregon. Ms. Cabraser will discuss “Class Action Objectors/2018 Rule 23 Amendments” on the symposium’s first day at 3:15 p.m.

The event, co-sponsored by the Pound Civil Justice Institute and Lewis & Clark Law School, will include presentations by faculty who have co-authored eleven academic papers on access to justice in aggregate litigation. Faculty will also speak on an array of topics relating to class action law including: “The Roles of Attorneys in MDLs,” Class Actions and Social Justice Reform,” and “The Future of Mass Torts.”

For more details about the symposium and to view the full list of faculty and topics, click here.

About Elizabeth Cabraser

Name partner and co-founder of Lieff Cabraser, Elizabeth Cabraser chairs the firm’s personal injury and environmental litigation practice groups. One of the nation’s leading class action litigators and possessing unparalleled expertise in complex civil litigation, she has served as court-appointed lead, co-lead, or class counsel in scores of federal multi-district and state coordinated proceedings. Today, she serves in court-appointed leadership positions in several of the nation’s highest profile civil cases, including a solo leadership role in the VW “Clean Diesel” Emissions case, as well as lead positions in the GM ignition switch defect and Takata defective airbag cases, and the recently-filed Fiat Chrysler Jeep Dodge diesel emissions fraud litigationGeneric Drugs Pricing antitrust litigation, and the National Prescription Opiates litigation.